-
Mashup Score: 0
The combination of revumenib plus decitabine/cedazuridine showed high rates of remission among patients with relapsed/refractory AML with KMT2Ar, NPM1mt, and NUP98r genetic alterations.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
In line with its safety and efficacy profile, T-DXd preserved quality of life and neurological function in patients with HER2-positive metastatic breast cancer, irrespective of brain metastases.
Source: www.oncnursingnews.comCategories: General Medicine News, NursingTweet-
Findings from the phase 3b/4 DESTINY-Breast12 trials shows that T-DXd preserved quality of life and neurological function in patients with HER2-positive metastatic breast cancer, irrespective of brain metastases. Read more: https://t.co/7reS99S0SP
-
-
Mashup Score: 0FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC - 3 day(s) ago
The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA approved encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6 for the treatment of BRAF V600E-mutated metastatic colorectal cancer: https://t.co/KewgccP7yx
-
-
Mashup Score: 0
Treatment sequencing with targeted therapies may help to improve overall survival, according to real-world data.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
Real-world data suggest optimal CLL/SLL treatment sequencing involves targeted therapies, including covalent BTKis and BCL2 inhibitors, for better survival outcomes. Read more at https://t.co/mfG4BZ5GPc
-
-
Mashup Score: 2
APPs provide an in-depth look at amivantamab plus lazertinib for the treatment of patients with locally advanced or metastatic non–small cell lung cancer.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
On August 20, 2024, the FDA approved amivantamab plus lazertinib as a first-line chemotherapy-free treatment of locally advanced or metastatic non–small cell lung cancer. Check out our Rx Road Map to learn more: https://t.co/mqjQ7KPq8W https://t.co/0QJoyAwsyS
-
-
Mashup Score: 1
Perioperative atezolizumab did not improve outcomes in patients with triple-negative breast cancer.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
Results presented at the 2024 San Antonio Breast Cancer Symposium showed that Perioperative atezolizumab did not improve outcomes in patients with triple-negative breast cancer. For more information, go to https://t.co/a2N2AGOeku
-
-
Mashup Score: 0
The combination of selinexor with ruxolitinib, in both 40mg and 60mg doses, demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis.
Source: www.oncnursingnews.comCategories: General Medicine News, NursingTweet-
Data presented at the 2024 ASH Annual Meeting demonstrate that the combination of selinexor and ruxolitinib was both safe and effective for patients with myelofibrosis. For more information, visit https://t.co/peOxQiacvL
-
-
Mashup Score: 0
High-grade immune-related adverse effects occurred in 18.9% of older patients with early-stage breast cancer treated with immune checkpoint inhibitors, according to a multi-institutional study.
Source: www.oncnursingnews.comCategories: General Medicine News, NursingTweet-
A study at the 2024 @SABCSSanAntonio reveals that older patients with early-stage breast cancer who are treated with immune checkpoint inhibitors face an elevated risk of developing severe immune-related adverse effects. Read more: https://t.co/umCQdOXaAc https://t.co/iThEcEMNCX
-
-
Mashup Score: 0Optimizing Management of Chronic GVHD: The Care Team’s Role in Symptom Management and Patient Care - 11 day(s) ago
Experts explore chronic graft-versus-host disease (cGVHD), discussing its symptoms, patient impact, treatment approaches including emerging therapies like axatilimab, and strategies for symptom management and patient education, while emphasizing the importance of multidisciplinary care and looking towards future advancements in GVHD management.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
What does the future hold for cGVHD management? Find out in Oncology Nursing News Expert Connections, where experts discuss innovative treatments like axatilimab, multidisciplinary care, and strategies to empower patients. Watch now: https://t.co/w31ORikLDH
-
-
Mashup Score: 0Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers - 12 day(s) ago
Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
Data from the phase 1/2 GLIMMER-01 trial shows that combining E-602 with cemiplimab demonstrated anti-tumor effects in patients with PD-L1-resistant solid tumors, including non-small cell lung cancer (NSCLC) and melanoma. For more information, visit https://t.co/KxVnwqVCkc
-
Findings from the phase 1/2 SAVE study shows that Treatment with all-oral revumenib plus decitabine/cedazuridine and venetoclax induced high rates of remission in some patients with relapsed/refractory acute myeloid leukemia. Read more here: https://t.co/UEO4KNKjcs